ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Meme Coin Doge is worth more than PMN

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on Dec 14, 2021 12:55pm

127 Views

Post# 34229517

RE:Meme Coin Doge is worth more than PMN

Why an NR\ PR .. this was part of the plan and to be expected, you got to have the stomach to handle it. Heck ! It may drop to .07/.08 quote=DavidKingCanada]We need some sort of PR before the Price drops below 0.10
This was bound to happen before Consolidation. [/quote]

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs